Valeritas Holdings Inc 뉴스 - VLRX | 주식 나스닥

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FO...

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage

BRIDGEWATER, N.J., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical...

Quarterly Report (10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FO...

Valeritas Announces Third Quarter 2019 Financial Results

BRIDGEWATER, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical...

Valeritas Presents Positive h-Patch™ Apomorphine Study Data at the World Congress of Neurology (WCN 2019)

BRIDGEWATER, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical...

Valeritas to Report Third Quarter 2019 Financial Results on November 12, 2019

BRIDGEWATER, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FO...

GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclin...

BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical...

Valeritas Presents Positive h-Patch™ Apomorphine Study Data at Global Experts Meeting on Frontiers in Alzheimer’s Disease...

BRIDGEWATER, N.J., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical...

Valeritas Announces Poster Presentation of Preclinical h-Patch™ Cannabidiol (CBD) Study at the American Epilepsy Society's ...

BRIDGEWATER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical...

Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the World Congress of Neurology (WCN 2...

BRIDGEWATER, N.J., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical...

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Valeritas Holdings Inc (VLRX)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

VLRX 뉴스

Current Report Filing (8-k)

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage

Quarterly Report (10-q)

Current Report Filing (8-k)

Valeritas Announces Third Quarter 2019 Financial Results

Valeritas Presents Positive h-Patch™ Apomorphine Study Data at the World Congress of Neurology (WCN 2019)

Valeritas to Report Third Quarter 2019 Financial Results on November 12, 2019

Current Report Filing (8-k)

GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclin...

Valeritas Presents Positive h-Patch™ Apomorphine Study Data at Global Experts Meeting on Frontiers in Alzheimer’s Disease...

Valeritas Announces Poster Presentation of Preclinical h-Patch™ Cannabidiol (CBD) Study at the American Epilepsy Society's ...

Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the World Congress of Neurology (WCN 2...

Amended Quarterly Report (10-q/a)

Amended Quarterly Report (10-q/a)

Valeritas Hosts Educational Symposium and Participates in the Metabolic & Endocrine Disease Summit (MEDS) East

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Valeritas Holdings Inc (VLRX) 뉴스

Valeritas Holdings Inc (VLRX)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

VLRX 뉴스

Current Report Filing (8-k)

Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage

Quarterly Report (10-q)

Current Report Filing (8-k)

Valeritas Announces Third Quarter 2019 Financial Results

Valeritas Presents Positive h-Patch™ Apomorphine Study Data at the World Congress of Neurology (WCN 2019)

Valeritas to Report Third Quarter 2019 Financial Results on November 12, 2019

Current Report Filing (8-k)

GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclin...

Valeritas Presents Positive h-Patch™ Apomorphine Study Data at Global Experts Meeting on Frontiers in Alzheimer’s Disease...

Valeritas Announces Poster Presentation of Preclinical h-Patch™ Cannabidiol (CBD) Study at the American Epilepsy Society's ...

Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the World Congress of Neurology (WCN 2...

Amended Quarterly Report (10-q/a)

Amended Quarterly Report (10-q/a)

Valeritas Hosts Educational Symposium and Participates in the Metabolic & Endocrine Disease Summit (MEDS) East

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거